These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15231683)

  • 1. Kohonen maps for prediction of binding to human cytochrome P450 3A4.
    Balakin KV; Ekins S; Bugrim A; Ivanenkov YA; Korolev D; Nikolsky YV; Skorenko AV; Ivashchenko AA; Savchuk NP; Nikolskaya T
    Drug Metab Dispos; 2004 Oct; 32(10):1183-9. PubMed ID: 15231683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
    Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
    J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates.
    Balakin KV; Ekins S; Bugrim A; Ivanenkov YA; Korolev D; Nikolsky YV; Ivashchenko AA; Savchuk NP; Nikolskaya T
    Drug Metab Dispos; 2004 Oct; 32(10):1111-20. PubMed ID: 15269187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of small-molecule binding to cytochrome P450 3A4: flexible docking combined with multidimensional QSAR.
    Lill MA; Dobler M; Vedani A
    ChemMedChem; 2006 Jan; 1(1):73-81. PubMed ID: 16892339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4.
    Ekins S; Berbaum J; Harrison RK
    Drug Metab Dispos; 2003 Sep; 31(9):1077-80. PubMed ID: 12920160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450.
    Stjernschantz E; Vermeulen NP; Oostenbrink C
    Expert Opin Drug Metab Toxicol; 2008 May; 4(5):513-27. PubMed ID: 18484912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate modeling of cytochrome P450 3A4 inhibition.
    Kriegl JM; Eriksson L; Arnhold T; Beck B; Johansson E; Fox T
    Eur J Pharm Sci; 2005 Apr; 24(5):451-63. PubMed ID: 15784335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new standardized electrochemical array for drug metabolic profiling with human cytochromes P450.
    Fantuzzi A; Mak LH; Capria E; Dodhia V; Panicco P; Collins S; Gilardi G
    Anal Chem; 2011 May; 83(10):3831-9. PubMed ID: 21469680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
    Brandes LJ; Queen GM; LaBella FS
    Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive computational assessment of ADME properties using mapping techniques.
    Balakin KV; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Ekins S
    Curr Drug Discov Technol; 2005 Jun; 2(2):99-113. PubMed ID: 16472234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors.
    Jensen BF; Vind C; Padkjaer SB; Brockhoff PB; Refsgaard HH
    J Med Chem; 2007 Feb; 50(3):501-11. PubMed ID: 17266202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli.
    Vail RB; Homann MJ; Hanna I; Zaks A
    J Ind Microbiol Biotechnol; 2005 Feb; 32(2):67-74. PubMed ID: 15739102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone.
    Williams PA; Cosme J; Vinkovic DM; Ward A; Angove HC; Day PJ; Vonrhein C; Tickle IJ; Jhoti H
    Science; 2004 Jul; 305(5684):683-6. PubMed ID: 15256616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates.
    Crivori P; Zamora I; Speed B; Orrenius C; Poggesi I
    J Comput Aided Mol Des; 2004 Mar; 18(3):155-66. PubMed ID: 15368916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
    Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
    Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.